Springhill Fund Asset Management HK Co Ltd Buys Shares of 207,600 ABIVAX Société Anonyme (NASDAQ:ABVX)

Springhill Fund Asset Management HK Co Ltd purchased a new position in shares of ABIVAX Société Anonyme (NASDAQ:ABVX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 207,600 shares of the company’s stock, valued at approximately $1,520,000. ABIVAX Société Anonyme makes up about 2.5% of Springhill Fund Asset Management HK Co Ltd’s investment portfolio, making the stock its 16th biggest holding.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC acquired a new position in shares of ABIVAX Société Anonyme in the 4th quarter valued at approximately $29,000. R Squared Ltd acquired a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $36,000. BNP Paribas Financial Markets increased its position in shares of ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares in the last quarter. abrdn plc raised its holdings in shares of ABIVAX Société Anonyme by 34.1% during the fourth quarter. abrdn plc now owns 424,181 shares of the company’s stock worth $3,105,000 after acquiring an additional 107,750 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $5,336,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. JMP Securities reiterated a “market outperform” rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price objective on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $38.00.

ABIVAX Société Anonyme Trading Down 8.1 %

Shares of ABVX stock opened at $5.32 on Friday. The firm’s fifty day moving average price is $6.77 and its two-hundred day moving average price is $8.14. ABIVAX Société Anonyme has a 1 year low of $5.16 and a 1 year high of $16.63.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.